Quotient Sciences extends formulation and manufacturing operations in UK
The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels. Quotient Sciences CEO Mark Egerton said:
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.